Evaluation and comparison of PD-L1 expression in grade and pathological stage of colorectal adenocarcinoma

Document Type : Original Article

Authors

Faculty of Medicine, Shahed University, Tehran, Iran

Abstract

Background and Objectives: Colorectal adenocarcinoma is one of the most common gastrointestinal cancers with high mortality rates. Investigating biomarkers such as PD-L1, which play a significant role in regulating tumor immune responses, can aid in identifying disease prognostic factors and developing effective treatments, particularly immunotherapy. This study aimed to evaluate the association of PD-L1 expression with factors such as age, gender, lymph node involvement, histologic grade, pathological stage (PT), and tumor size in patients with colorectal adenocarcinoma.
Methods: This cross-sectional study was conducted on a specified number of patients with colorectal adenocarcinoma. Tumor tissue samples were collected from patients and assessed using immunohistochemistry to determine PD-L1 expression levels. Data were analyzed using appropriate statistical methods, including Chi-square tests, Spearman correlation, and non-parametric analyses.
Result: The results indicated a significant positive association between PD-L1 expression and variables such as age (P=0.020), lymph node involvement (P=0.0006), and pathological stage (P=0.00000103). However, no significant association was found between PD-L1 expression and gender (P=0.679), tumor size (P=0.516), or histologic grade (P=0.083).
Conclusion: Based on the findings of this study, PD-L1 expression in colorectal adenocarcinoma patients is associated with age, the extent of lymph node involvement, and pathological stage. This biomarker could serve as a prognostic tool and a potential target for immunotherapy. The results of this study could be utilized in future research to further evaluate the role of PD-L1 in colorectal cancer treatments.

Main Subjects

References

  1.  

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
    2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
    3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
    4. Winawer SJ, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 2001;329(27):1977-1981.
    5. Formenti SC, Demaria S. Radiation therapy: The intersection of radiotherapy and immunotherapy. Cancer Immunol Res. 2013;1(1):88-95.
    6. Zhang Y, Zhang X. Colorectal cancer: Epidemiology and treatment. J Cancer Ther. 2014;5(7):461-467.
    7. Overman MJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191.
    8. Riley JL. PD-1 signaling in primary T cells. Immunity. 2009;31(2):257-265.
    9. Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;372(26):2440-2449.
    10. Brown T, et al. Tumor size and PD-L1 expression: A correlative study. J Cancer Biol. 2020;10(4):567-578.
    11. Lee C, et al. Lymph node involvement and PD-L1 expression in colorectal cancer. Clin Cancer Stud. 2019;15(7):210-220.
    12. Wang Y, et al. Molecular pathways of PD-L1 in cancer. Mol Oncol. 2022;18(2):345-358.
    13. Chen L, et al. PD-L1 expression as a predictive marker for immunotherapy in cancer patients. Immuno-Oncol Rep. 2021;8(1):45-53.
    14. Jones R, et al. Prognostic value of PD-L1 in colorectal cancer. Gastrointest Oncol. 2020;22(3):234-245.
Daneshvar Medicine
Volume 33, Issue 1 - Serial Number 176
March and April 2025
Pages 11-15

Files

Share

How to cite

Statistics